The University of Southampton
×
Filter your search:
University of Southampton Institutional Repository

Mirikizumab for treating moderately to severely active ulcerative colitis: a single technology appraisal

Mirikizumab for treating moderately to severely active ulcerative colitis: a single technology appraisal
Mirikizumab for treating moderately to severely active ulcerative colitis: a single technology appraisal
The company (Eli Lilly) submitted evidence to NICE for mirikizumab, in the treatment of people with moderately to severely active ulcerative colitis (UC), to be considered under NICE’s proportionate approach to technology appraisals (PATT) streamlined cost-comparison process. This report is the external assessment group’s (EAG’s) critique of the company’s submission (CS). It identifies the strengths and weaknesses of the CS.
National Institute for Health and Care Excellence
Pickett, Karen
1bac9d88-da29-4a3e-9fd2-e469f129f963
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Maund, Emma
c9733167-eafe-44e5-b418-5ace79161402
Peters, Jaime
4d0100aa-0265-47bf-ac8e-d045076f8b2a
Takahashi, Marcia
fa084efd-dc46-4325-8fc9-d3f6d1f8b5d0
Picot, Joanna
324d6f20-a105-49fd-9fb0-88791be84ada
Pickett, Karen
1bac9d88-da29-4a3e-9fd2-e469f129f963
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Maund, Emma
c9733167-eafe-44e5-b418-5ace79161402
Peters, Jaime
4d0100aa-0265-47bf-ac8e-d045076f8b2a
Takahashi, Marcia
fa084efd-dc46-4325-8fc9-d3f6d1f8b5d0
Picot, Joanna
324d6f20-a105-49fd-9fb0-88791be84ada

Pickett, Karen, Kalita, Neelam, Maund, Emma, Peters, Jaime, Takahashi, Marcia and Picot, Joanna (2023) Mirikizumab for treating moderately to severely active ulcerative colitis: a single technology appraisal (Health Technology Assessment) National Institute for Health and Care Excellence 72pp.

Record type: Monograph (Project Report)

Abstract

The company (Eli Lilly) submitted evidence to NICE for mirikizumab, in the treatment of people with moderately to severely active ulcerative colitis (UC), to be considered under NICE’s proportionate approach to technology appraisals (PATT) streamlined cost-comparison process. This report is the external assessment group’s (EAG’s) critique of the company’s submission (CS). It identifies the strengths and weaknesses of the CS.

Text
Mirikizumab ID3973 EAG Report - Version of Record
Available under License Other.
Download (1MB)

More information

Published date: 25 October 2023
Related URLs:

Identifiers

Local EPrints ID: 484623
URI: http://eprints.soton.ac.uk/id/eprint/484623
PURE UUID: e528ca26-175c-47ee-bebc-ab43ac0b9607
ORCID for Karen Pickett: ORCID iD orcid.org/0000-0002-8631-6465
ORCID for Neelam Kalita: ORCID iD orcid.org/0000-0002-0973-0160
ORCID for Emma Maund: ORCID iD orcid.org/0000-0002-3998-6669
ORCID for Marcia Takahashi: ORCID iD orcid.org/0000-0002-6932-2660
ORCID for Joanna Picot: ORCID iD orcid.org/0000-0001-5987-996X

Catalogue record

Date deposited: 17 Nov 2023 18:09
Last modified: 11 Sep 2024 02:31

Export record

Contributors

Author: Karen Pickett ORCID iD
Author: Neelam Kalita ORCID iD
Author: Emma Maund ORCID iD
Author: Jaime Peters
Author: Marcia Takahashi ORCID iD
Author: Joanna Picot ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Library staff additional information
Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×